Evidence network for deaths_(OS)

1IMpassion-031 (all population), 20201Alice, 20221ALEXANDRA/IMpassion-030, 20241NSABP B-59/GBG 96-GeparDouze, 20183IMpassion-132 (ITT population), 2024 IMpassion-132 (PD-L1 positive population), 2024 TBCRC, 20248KEYNOTE-119 (PDL1 CPS>1), 2019 KEYNOTE-119 (PDL1 CPS>10), 2019 KEYNOTE-119 (all population), 2019 KEYNOTE-119 (all population) DUPLICATE, 2019 KEYNOTE-119 (PD-L1 CPS of 1 or more) DUPLICATE, 2019 KEYNOTE-119 (PD-L1 CPS of 10 or more), 2019 KEYNOTE-119 (PD-L1 positive CPS = 10 or more), 2019 KEYNOTE-119 PD-L1 positive (CPS = 1 or more), 20192IMpassion-130 (all population), 2018 IMpassion-130 (PDL1>1%), 20184KEYNOTE-355 (all population), 2020 KEYNOTE-355 (CPS>1), 2020 KEYNOTE-355 (CPS>10), 2020 KEYNOTE-522, 20202IMpassion-131 (PD-L1 > 1%), 2020 IMpassion-131 (all population), 20202A-Brave, 2024 A-Brave Stratum A, 20241EMBRACA, 20181OlympiAD, 20171OlympiA (BIG 6-13, NSABP B-55), 02ASCENT (all population), 2021 ASCENT (patients without brain metastases), 20212PAKT (all population), 2020 PAKT (PIK3CA/AKT1/PTEN-altered), 20201LOTUS, 20171BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 20182TORCHLIGHT, 2024 TORCHLIGHT PDL 1 positive population, 20241BCTOP-T-A01 arm A/B, 2024atezolizumab plus nab-paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.18 [0.43; 3.26]1.18 [0.43;3.26]atezolizumab plus nab-paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.18 [0.43; 3.26]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel atezolizumab plus nab-paclitaxel better 0.73 [0.57; 0.94]0.73 [0.57;0.94]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel atezolizumab plus nab-paclitaxel better 0.73 [0.57; 0.94]atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel 1.45 [0.90; 2.33]1.45 [0.90;2.33]atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel 1.45 [0.90; 2.33]atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel 1.02 [0.62; 1.67]1.02 [0.62;1.67]atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel 1.02 [0.62; 1.67]atezolizumab plus nab-paclitaxel vs. olaparib 0.91 [0.64; 1.28]0.91 [0.64;1.28]atezolizumab plus nab-paclitaxel vs. olaparib 0.91 [0.64; 1.28]atezolizumab plus nab-paclitaxel vs. pembrolizumab alone 0.90 [0.75; 1.09]0.90 [0.75;1.09]atezolizumab plus nab-paclitaxel vs. pembrolizumab alone 0.90 [0.75; 1.09]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.96 [0.80; 1.15]0.96 [0.80;1.15]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.96 [0.80; 1.15]atezolizumab plus nab-paclitaxel vs. placebo 0.62 [0.37; 1.01]0.62 [0.37;1.01]atezolizumab plus nab-paclitaxel vs. placebo 0.62 [0.37; 1.01]atezolizumab plus nab-paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 1.64 [1.33; 2.03]1.64 [1.33;2.03]atezolizumab plus nab-paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 1.64 [1.33; 2.03]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.81 [0.70; 0.94]0.81 [0.70;0.94]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.81 [0.70; 0.94]atezolizumab plus nab-paclitaxel vs. talazoparib 0.96 [0.73; 1.27]0.96 [0.73;1.27]atezolizumab plus nab-paclitaxel vs. talazoparib 0.96 [0.73; 1.27]atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.99 [0.57; 1.72]0.99 [0.57;1.72]atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.99 [0.57; 1.72]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus nab-paclitaxel 0.85 [0.31; 2.34]0.85 [0.31;2.34]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus nab-paclitaxel 0.85 [0.31; 2.34]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus paclitaxel 0.62 [0.22; 1.72]0.62 [0.22;1.72]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus paclitaxel 0.62 [0.22; 1.72]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. capivasertib plus paclitaxel 1.23 [0.41; 3.69]1.23 [0.41;3.69]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. capivasertib plus paclitaxel 1.23 [0.41; 3.69]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. ipatasertib plus paclitaxel 0.86 [0.28; 2.62]0.86 [0.28;2.62]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. ipatasertib plus paclitaxel 0.86 [0.28; 2.62]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. olaparib 0.77 [0.27; 2.20]0.77 [0.27;2.20]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. olaparib 0.77 [0.27; 2.20]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab alone 0.77 [0.28; 2.11]0.77 [0.28;2.11]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab alone 0.77 [0.28; 2.11]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab plus SoC 0.81 [0.29; 2.23]0.81 [0.29;2.23]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab plus SoC 0.81 [0.29; 2.23]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo 0.52 [0.17; 1.59]0.52 [0.17;1.59]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo 0.52 [0.17; 1.59]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. sacituzumab govitecan 1.39 [0.50; 3.85]1.39 [0.50;3.85]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. sacituzumab govitecan 1.39 [0.50; 3.85]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. Standard of Care (SoC) 0.69 [0.25; 1.89]0.69 [0.25;1.89]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. Standard of Care (SoC) 0.69 [0.25; 1.89]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. talazoparib 0.81 [0.29; 2.29]0.81 [0.29;2.29]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. talazoparib 0.81 [0.29; 2.29]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. veliparib plus paclitaxel plus carboplatin 0.84 [0.27; 2.62]0.84 [0.27;2.62]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. veliparib plus paclitaxel plus carboplatin 0.84 [0.27; 2.62]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.37 [1.07; 1.77]1.37 [1.07;1.77]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.37 [1.07; 1.77]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.62 [0.58; 4.52]1.62 [0.58;4.52]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.62 [0.58; 4.52]atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.99 [1.21; 3.26]1.99 [1.21;3.26]atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.99 [1.21; 3.26]atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel 1.40 [0.84; 2.33]1.40 [0.84;2.33]atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel 1.40 [0.84; 2.33]atezolizumab plus paclitaxel vs. olaparib 1.24 [0.85; 1.80]1.24 [0.85;1.80]atezolizumab plus paclitaxel vs. olaparib 1.24 [0.85; 1.80]atezolizumab plus paclitaxel vs. pembrolizumab alone 1.24 [0.98; 1.57]1.24 [0.98;1.57]atezolizumab plus paclitaxel vs. pembrolizumab alone 1.24 [0.98; 1.57]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.31 [1.04; 1.66]1.31 [1.04;1.66]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.31 [1.04; 1.66]atezolizumab plus paclitaxel vs. placebo 0.84 [0.50; 1.42]0.84 [0.50;1.42]atezolizumab plus paclitaxel vs. placebo 0.84 [0.50; 1.42]atezolizumab plus paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 2.25 [1.75; 2.91]2.25 [1.75;2.91]atezolizumab plus paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 2.25 [1.75; 2.91]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.12 [0.91; 1.37]1.12 [0.91;1.37]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.12 [0.91; 1.37]atezolizumab plus paclitaxel vs. talazoparib 1.32 [0.96; 1.80]1.32 [0.96;1.80]atezolizumab plus paclitaxel vs. talazoparib 1.32 [0.96; 1.80]atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.36 [0.77; 2.40]1.36 [0.77;2.40]atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.36 [0.77; 2.40]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.69 [0.43; 1.11]0.69 [0.43;1.11]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.69 [0.43; 1.11]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.82 [0.27; 2.45]0.82 [0.27;2.45]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.82 [0.27; 2.45]capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel capivasertib plus paclitaxel better 0.50 [0.31; 0.83]0.50 [0.31;0.83]capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel capivasertib plus paclitaxel better 0.50 [0.31; 0.83]capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel 0.70 [0.37; 1.35]0.70 [0.37;1.35]capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel 0.70 [0.37; 1.35]capivasertib plus paclitaxel vs. olaparib 0.62 [0.36; 1.08]0.62 [0.36;1.08]capivasertib plus paclitaxel vs. olaparib 0.62 [0.36; 1.08]capivasertib plus paclitaxel vs. pembrolizumab alone capivasertib plus paclitaxel better 0.62 [0.39; 0.99]0.62 [0.39;0.99]capivasertib plus paclitaxel vs. pembrolizumab alone capivasertib plus paclitaxel better 0.62 [0.39; 0.99]capivasertib plus paclitaxel vs. pembrolizumab plus SoC 0.66 [0.42; 1.05]0.66 [0.42;1.05]capivasertib plus paclitaxel vs. pembrolizumab plus SoC 0.66 [0.42; 1.05]capivasertib plus paclitaxel vs. placebo capivasertib plus paclitaxel better 0.42 [0.22; 0.82]0.42 [0.22;0.82]capivasertib plus paclitaxel vs. placebo capivasertib plus paclitaxel better 0.42 [0.22; 0.82]capivasertib plus paclitaxel vs. sacituzumab govitecan 1.13 [0.71; 1.82]1.13 [0.71;1.82]capivasertib plus paclitaxel vs. sacituzumab govitecan 1.13 [0.71; 1.82]capivasertib plus paclitaxel vs. Standard of Care (SoC) capivasertib plus paclitaxel better 0.56 [0.36; 0.88]0.56 [0.36;0.88]capivasertib plus paclitaxel vs. Standard of Care (SoC) capivasertib plus paclitaxel better 0.56 [0.36; 0.88]capivasertib plus paclitaxel vs. talazoparib 0.66 [0.40; 1.10]0.66 [0.40;1.10]capivasertib plus paclitaxel vs. talazoparib 0.66 [0.40; 1.10]capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.69 [0.34; 1.37]0.69 [0.34;1.37]capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.69 [0.34; 1.37]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.98 [0.60; 1.61]0.98 [0.60;1.61]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.98 [0.60; 1.61]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.16 [0.38; 3.52]1.16 [0.38;3.52]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.16 [0.38; 3.52]ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel 0.72 [0.43; 1.20]0.72 [0.43;1.20]ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel 0.72 [0.43; 1.20]ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel 1.42 [0.74; 2.73]1.42 [0.74;2.73]ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel 1.42 [0.74; 2.73]ipatasertib plus paclitaxel vs. olaparib 0.89 [0.51; 1.56]0.89 [0.51;1.56]ipatasertib plus paclitaxel vs. olaparib 0.89 [0.51; 1.56]ipatasertib plus paclitaxel vs. pembrolizumab alone 0.89 [0.55; 1.44]0.89 [0.55;1.44]ipatasertib plus paclitaxel vs. pembrolizumab alone 0.89 [0.55; 1.44]ipatasertib plus paclitaxel vs. pembrolizumab plus SoC 0.94 [0.58; 1.52]0.94 [0.58;1.52]ipatasertib plus paclitaxel vs. pembrolizumab plus SoC 0.94 [0.58; 1.52]ipatasertib plus paclitaxel vs. placebo 0.60 [0.31; 1.18]0.60 [0.31;1.18]ipatasertib plus paclitaxel vs. placebo 0.60 [0.31; 1.18]ipatasertib plus paclitaxel vs. sacituzumab govitecan 1.61 [0.99; 2.64]1.61 [0.99;2.64]ipatasertib plus paclitaxel vs. sacituzumab govitecan 1.61 [0.99; 2.64]ipatasertib plus paclitaxel vs. Standard of Care (SoC) 0.80 [0.50; 1.28]0.80 [0.50;1.28]ipatasertib plus paclitaxel vs. Standard of Care (SoC) 0.80 [0.50; 1.28]ipatasertib plus paclitaxel vs. talazoparib 0.94 [0.56; 1.60]0.94 [0.56;1.60]ipatasertib plus paclitaxel vs. talazoparib 0.94 [0.56; 1.60]ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.98 [0.48; 1.98]0.98 [0.48;1.98]ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.98 [0.48; 1.98]olaparib vs. atezolizumab plus nab-paclitaxel 1.10 [0.78; 1.56]1.10 [0.78;1.56]olaparib vs. atezolizumab plus nab-paclitaxel 1.10 [0.78; 1.56]olaparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.30 [0.46; 3.74]1.30 [0.46;3.74]olaparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.30 [0.46; 3.74]olaparib vs. atezolizumab plus paclitaxel 0.81 [0.55; 1.17]0.81 [0.55;1.17]olaparib vs. atezolizumab plus paclitaxel 0.81 [0.55; 1.17]olaparib vs. capivasertib plus paclitaxel 1.60 [0.93; 2.77]1.60 [0.93;2.77]olaparib vs. capivasertib plus paclitaxel 1.60 [0.93; 2.77]olaparib vs. ipatasertib plus paclitaxel 1.12 [0.64; 1.98]1.12 [0.64;1.98]olaparib vs. ipatasertib plus paclitaxel 1.12 [0.64; 1.98]olaparib vs. pembrolizumab alone 1.00 [0.71; 1.39]1.00 [0.71;1.39]olaparib vs. pembrolizumab alone 1.00 [0.71; 1.39]olaparib vs. pembrolizumab plus SoC 1.06 [0.76; 1.47]1.06 [0.76;1.47]olaparib vs. pembrolizumab plus SoC 1.06 [0.76; 1.47]olaparib vs. placebo olaparib better 0.68 [0.47; 0.98]0.68 [0.47;0.98]olaparib vs. placebo olaparib better 0.68 [0.47; 0.98]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]1.82 [1.28;2.57]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]0.90 [0.66;1.23]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]olaparib vs. talazoparib 1.06 [0.72; 1.57]1.06 [0.72;1.57]olaparib vs. talazoparib 1.06 [0.72; 1.57]olaparib vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.59; 2.03]1.10 [0.59;2.03]olaparib vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.59; 2.03]pembrolizumab alone vs. atezolizumab plus nab-paclitaxel 1.11 [0.91; 1.34]1.11 [0.91;1.34]pembrolizumab alone vs. atezolizumab plus nab-paclitaxel 1.11 [0.91; 1.34]pembrolizumab alone vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.31 [0.47; 3.60]1.31 [0.47;3.60]pembrolizumab alone vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.31 [0.47; 3.60]pembrolizumab alone vs. atezolizumab plus paclitaxel 0.81 [0.64; 1.03]0.81 [0.64;1.03]pembrolizumab alone vs. atezolizumab plus paclitaxel 0.81 [0.64; 1.03]pembrolizumab alone vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.60 [1.01; 2.56]1.60 [1.01;2.56]pembrolizumab alone vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.60 [1.01; 2.56]pembrolizumab alone vs. ipatasertib plus paclitaxel 1.13 [0.69; 1.83]1.13 [0.69;1.83]pembrolizumab alone vs. ipatasertib plus paclitaxel 1.13 [0.69; 1.83]pembrolizumab alone vs. olaparib 1.00 [0.72; 1.40]1.00 [0.72;1.40]pembrolizumab alone vs. olaparib 1.00 [0.72; 1.40]pembrolizumab alone vs. pembrolizumab plus SoC 1.06 [0.90; 1.25]1.06 [0.90;1.25]pembrolizumab alone vs. pembrolizumab plus SoC 1.06 [0.90; 1.25]pembrolizumab alone vs. placebo 0.68 [0.42; 1.12]0.68 [0.42;1.12]pembrolizumab alone vs. placebo 0.68 [0.42; 1.12]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.50; 2.21]1.82 [1.50;2.21]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.50; 2.21]pembrolizumab alone vs. Standard of Care (SoC) 0.90 [0.80; 1.02]0.90 [0.80;1.02]pembrolizumab alone vs. Standard of Care (SoC) 0.90 [0.80; 1.02]pembrolizumab alone vs. talazoparib 1.06 [0.82; 1.39]1.06 [0.82;1.39]pembrolizumab alone vs. talazoparib 1.06 [0.82; 1.39]pembrolizumab alone vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.64; 1.89]1.10 [0.64;1.89]pembrolizumab alone vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.64; 1.89]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.04 [0.87; 1.26]1.04 [0.87;1.26]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.04 [0.87; 1.26]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.45; 3.39]1.23 [0.45;3.39]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.45; 3.39]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel pembrolizumab plus SoC better 0.76 [0.60; 0.96]0.76 [0.60;0.96]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel pembrolizumab plus SoC better 0.76 [0.60; 0.96]pembrolizumab plus SoC vs. capivasertib plus paclitaxel 1.51 [0.95; 2.41]1.51 [0.95;2.41]pembrolizumab plus SoC vs. capivasertib plus paclitaxel 1.51 [0.95; 2.41]pembrolizumab plus SoC vs. ipatasertib plus paclitaxel 1.06 [0.66; 1.72]1.06 [0.66;1.72]pembrolizumab plus SoC vs. ipatasertib plus paclitaxel 1.06 [0.66; 1.72]pembrolizumab plus SoC vs. olaparib 0.95 [0.68; 1.32]0.95 [0.68;1.32]pembrolizumab plus SoC vs. olaparib 0.95 [0.68; 1.32]pembrolizumab plus SoC vs. pembrolizumab alone 0.94 [0.80; 1.11]0.94 [0.80;1.11]pembrolizumab plus SoC vs. pembrolizumab alone 0.94 [0.80; 1.11]pembrolizumab plus SoC vs. placebo 0.64 [0.39; 1.05]0.64 [0.39;1.05]pembrolizumab plus SoC vs. placebo 0.64 [0.39; 1.05]pembrolizumab plus SoC vs. sacituzumab govitecan sacituzumab govitecan better 1.72 [1.42; 2.07]1.72 [1.42;2.07]pembrolizumab plus SoC vs. sacituzumab govitecan sacituzumab govitecan better 1.72 [1.42; 2.07]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.85 [0.76; 0.95]0.85 [0.76;0.95]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.85 [0.76; 0.95]pembrolizumab plus SoC vs. talazoparib 1.00 [0.77; 1.30]1.00 [0.77;1.30]pembrolizumab plus SoC vs. talazoparib 1.00 [0.77; 1.30]pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin 1.04 [0.60; 1.78]1.04 [0.60;1.78]pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin 1.04 [0.60; 1.78]placebo vs. atezolizumab plus nab-paclitaxel 1.62 [0.99; 2.68]1.62 [0.99;2.68]placebo vs. atezolizumab plus nab-paclitaxel 1.62 [0.99; 2.68]placebo vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.92 [0.63; 5.84]1.92 [0.63;5.84]placebo vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.92 [0.63; 5.84]placebo vs. atezolizumab plus paclitaxel 1.18 [0.70; 1.99]1.18 [0.70;1.99]placebo vs. atezolizumab plus paclitaxel 1.18 [0.70; 1.99]placebo vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 2.35 [1.22; 4.54]2.35 [1.22;4.54]placebo vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 2.35 [1.22; 4.54]placebo vs. ipatasertib plus paclitaxel 1.65 [0.85; 3.23]1.65 [0.85;3.23]placebo vs. ipatasertib plus paclitaxel 1.65 [0.85; 3.23]placebo vs. olaparib olaparib better 1.47 [1.02; 2.11]1.47 [1.02;2.11]placebo vs. olaparib olaparib better 1.47 [1.02; 2.11]placebo vs. pembrolizumab alone 1.47 [0.90; 2.40]1.47 [0.90;2.40]placebo vs. pembrolizumab alone 1.47 [0.90; 2.40]placebo vs. pembrolizumab plus SoC 1.56 [0.95; 2.54]1.56 [0.95;2.54]placebo vs. pembrolizumab plus SoC 1.56 [0.95; 2.54]placebo vs. sacituzumab govitecan sacituzumab govitecan better 2.67 [1.62; 4.41]2.67 [1.62;4.41]placebo vs. sacituzumab govitecan sacituzumab govitecan better 2.67 [1.62; 4.41]placebo vs. Standard of Care (SoC) 1.32 [0.82; 2.13]1.32 [0.82;2.13]placebo vs. Standard of Care (SoC) 1.32 [0.82; 2.13]placebo vs. talazoparib 1.56 [0.92; 2.66]1.56 [0.92;2.66]placebo vs. talazoparib 1.56 [0.92; 2.66]placebo vs. veliparib plus paclitaxel plus carboplatin 1.61 [0.79; 3.29]1.61 [0.79;3.29]placebo vs. veliparib plus paclitaxel plus carboplatin 1.61 [0.79; 3.29]sacituzumab govitecan vs. atezolizumab plus nab-paclitaxel sacituzumab govitecan better 0.61 [0.49; 0.75]0.61 [0.49;0.75]sacituzumab govitecan vs. atezolizumab plus nab-paclitaxel sacituzumab govitecan better 0.61 [0.49; 0.75]sacituzumab govitecan vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.72 [0.26; 1.99]0.72 [0.26;1.99]sacituzumab govitecan vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.72 [0.26; 1.99]sacituzumab govitecan vs. atezolizumab plus paclitaxel sacituzumab govitecan better 0.44 [0.34; 0.57]0.44 [0.34;0.57]sacituzumab govitecan vs. atezolizumab plus paclitaxel sacituzumab govitecan better 0.44 [0.34; 0.57]sacituzumab govitecan vs. capivasertib plus paclitaxel 0.88 [0.55; 1.42]0.88 [0.55;1.42]sacituzumab govitecan vs. capivasertib plus paclitaxel 0.88 [0.55; 1.42]sacituzumab govitecan vs. ipatasertib plus paclitaxel 0.62 [0.38; 1.02]0.62 [0.38;1.02]sacituzumab govitecan vs. ipatasertib plus paclitaxel 0.62 [0.38; 1.02]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]0.55 [0.39;0.78]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.55 [0.45; 0.67]0.55 [0.45;0.67]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.55 [0.45; 0.67]sacituzumab govitecan vs. pembrolizumab plus SoC sacituzumab govitecan better 0.58 [0.48; 0.70]0.58 [0.48;0.70]sacituzumab govitecan vs. pembrolizumab plus SoC sacituzumab govitecan better 0.58 [0.48; 0.70]sacituzumab govitecan vs. placebo sacituzumab govitecan better 0.37 [0.23; 0.62]0.37 [0.23;0.62]sacituzumab govitecan vs. placebo sacituzumab govitecan better 0.37 [0.23; 0.62]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]0.50 [0.43;0.58]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]0.58 [0.44;0.77]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]sacituzumab govitecan vs. veliparib plus paclitaxel plus carboplatin 0.60 [0.35; 1.05]0.60 [0.35;1.05]sacituzumab govitecan vs. veliparib plus paclitaxel plus carboplatin 0.60 [0.35; 1.05]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.23 [1.06; 1.42]1.23 [1.06;1.42]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.23 [1.06; 1.42]Standard of Care (SoC) vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.45 [0.53; 3.96]1.45 [0.53;3.96]Standard of Care (SoC) vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.45 [0.53; 3.96]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.73; 1.10]0.90 [0.73;1.10]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.73; 1.10]Standard of Care (SoC) vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.78 [1.13; 2.79]1.78 [1.13;2.79]Standard of Care (SoC) vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.78 [1.13; 2.79]Standard of Care (SoC) vs. ipatasertib plus paclitaxel 1.25 [0.78; 2.00]1.25 [0.78;2.00]Standard of Care (SoC) vs. ipatasertib plus paclitaxel 1.25 [0.78; 2.00]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]1.11 [0.81;1.52]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]Standard of Care (SoC) vs. pembrolizumab alone 1.11 [0.98; 1.25]1.11 [0.98;1.25]Standard of Care (SoC) vs. pembrolizumab alone 1.11 [0.98; 1.25]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.18 [1.05; 1.31]1.18 [1.05;1.31]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.18 [1.05; 1.31]Standard of Care (SoC) vs. placebo 0.76 [0.47; 1.22]0.76 [0.47;1.22]Standard of Care (SoC) vs. placebo 0.76 [0.47; 1.22]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]2.02 [1.74;2.35]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]1.18 [0.93;1.49]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin 1.22 [0.72; 2.07]1.22 [0.72;2.07]Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin 1.22 [0.72; 2.07]talazoparib vs. atezolizumab plus nab-paclitaxel 1.04 [0.79; 1.37]1.04 [0.79;1.37]talazoparib vs. atezolizumab plus nab-paclitaxel 1.04 [0.79; 1.37]talazoparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.44; 3.45]1.23 [0.44;3.45]talazoparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.44; 3.45]talazoparib vs. atezolizumab plus paclitaxel 0.76 [0.56; 1.04]0.76 [0.56;1.04]talazoparib vs. atezolizumab plus paclitaxel 0.76 [0.56; 1.04]talazoparib vs. capivasertib plus paclitaxel 1.51 [0.91; 2.51]1.51 [0.91;2.51]talazoparib vs. capivasertib plus paclitaxel 1.51 [0.91; 2.51]talazoparib vs. ipatasertib plus paclitaxel 1.06 [0.63; 1.79]1.06 [0.63;1.79]talazoparib vs. ipatasertib plus paclitaxel 1.06 [0.63; 1.79]talazoparib vs. olaparib 0.94 [0.64; 1.39]0.94 [0.64;1.39]talazoparib vs. olaparib 0.94 [0.64; 1.39]talazoparib vs. pembrolizumab alone 0.94 [0.72; 1.23]0.94 [0.72;1.23]talazoparib vs. pembrolizumab alone 0.94 [0.72; 1.23]talazoparib vs. pembrolizumab plus SoC 1.00 [0.77; 1.29]1.00 [0.77;1.29]talazoparib vs. pembrolizumab plus SoC 1.00 [0.77; 1.29]talazoparib vs. placebo 0.64 [0.38; 1.09]0.64 [0.38;1.09]talazoparib vs. placebo 0.64 [0.38; 1.09]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]1.71 [1.29;2.26]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]0.85 [0.67;1.07]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]talazoparib vs. veliparib plus paclitaxel plus carboplatin 1.03 [0.58; 1.84]1.03 [0.58;1.84]talazoparib vs. veliparib plus paclitaxel plus carboplatin 1.03 [0.58; 1.84]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel 1.01 [0.58; 1.74]1.01 [0.58;1.74]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel 1.01 [0.58; 1.74]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.19 [0.38; 3.70]1.19 [0.38;3.70]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.19 [0.38; 3.70]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel 0.73 [0.42; 1.29]0.73 [0.42;1.29]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel 0.73 [0.42; 1.29]veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel 1.46 [0.73; 2.92]1.46 [0.73;2.92]veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel 1.46 [0.73; 2.92]veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel 1.02 [0.51; 2.08]1.02 [0.51;2.08]veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel 1.02 [0.51; 2.08]veliparib plus paclitaxel plus carboplatin vs. olaparib 0.91 [0.49; 1.68]0.91 [0.49;1.68]veliparib plus paclitaxel plus carboplatin vs. olaparib 0.91 [0.49; 1.68]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab alone 0.91 [0.53; 1.56]0.91 [0.53;1.56]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab alone 0.91 [0.53; 1.56]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC 0.96 [0.56; 1.65]0.96 [0.56;1.65]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC 0.96 [0.56; 1.65]veliparib plus paclitaxel plus carboplatin vs. placebo 0.62 [0.30; 1.26]0.62 [0.30;1.26]veliparib plus paclitaxel plus carboplatin vs. placebo 0.62 [0.30; 1.26]veliparib plus paclitaxel plus carboplatin vs. sacituzumab govitecan 1.65 [0.96; 2.86]1.65 [0.96;2.86]veliparib plus paclitaxel plus carboplatin vs. sacituzumab govitecan 1.65 [0.96; 2.86]veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC) 0.82 [0.48; 1.39]0.82 [0.48;1.39]veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC) 0.82 [0.48; 1.39]veliparib plus paclitaxel plus carboplatin vs. talazoparib 0.97 [0.54; 1.72]0.97 [0.54;1.72]veliparib plus paclitaxel plus carboplatin vs. talazoparib 0.97 [0.54; 1.72]nab-paclitaxelStandard of Care (SoC)pegylated liposomal doxorubicin and cyclophosphamidecarboplatingemcitabinenon active controlpaclitaxelplacebo plus SoCpaclitaxel followed by doxorubicin plus cyclophosphamideplacebonab-paclitaxel plus placebocarboplatin plus nab-paclitaxeldurvalumab alonepembrolizumab aloneatezolizumab plus nab-paclitaxelpembrolizumab plus SoCatezolizumab based treatmentavelumab aloneatezolizumab plus paclitaxeltalazoparibolaparibatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamidesacituzumab govitecancapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimabcamrelizumab aloneatezolizumab plus carboplatin plus nab-paclitaxelcamrelizumab plus SOCatezolizumab plus carboplatin plus paclitaxelgemcitabine plus platindocetaxelcyclophosphamidedirect evidencenetwork meta-analysis
T vs. C nab-paclitaxelStandard of Care (SoC)pegylated liposomal doxorubicin and cyclophosphamidecarboplatingemcitabinenon active controlpaclitaxelplacebo plus SoCpaclitaxel followed by doxorubicin plus cyclophosphamideplacebonab-paclitaxel plus placebocarboplatin plus nab-paclitaxeldurvalumab alonepembrolizumab aloneatezolizumab plus nab-paclitaxelpembrolizumab plus SoCatezolizumab based treatmentavelumab aloneatezolizumab plus paclitaxeltalazoparibolaparibatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamidesacituzumab govitecancapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimabcamrelizumab aloneatezolizumab plus carboplatin plus nab-paclitaxelcamrelizumab plus SOCatezolizumab plus carboplatin plus paclitaxelgemcitabine plus platindocetaxelcyclophosphamide
nab-paclitaxel---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Standard of Care (SoC)NA---NANANANANANANA0.76
0.47; 1.22		NANANA1.11
0.98; 1.25		1.23
1.06; 1.42		1.18
1.05; 1.31		NANA0.90
0.73; 1.10		1.18
0.93; 1.49		1.11
0.81; 1.52		1.45
0.53; 3.96		2.02
1.74; 2.35		1.78
1.13; 2.79		1.25
0.78; 2.00		1.22
0.72; 2.07		NANANANANANANANA
pegylated liposomal doxorubicin and cyclophosphamideNANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
carboplatinNANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
gemcitabineNANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
non active controlNANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
paclitaxelNANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANA
placebo plus SoCNANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANA
paclitaxel followed by doxorubicin plus cyclophosphamideNANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANA
placeboNA1.32
0.82; 2.13		NANANANANANANA---NANANA1.47
0.90; 2.40		1.62
0.99; 2.68		1.56
0.95; 2.54		NANA1.18
0.70; 1.99		1.56
0.92; 2.66		1.47
1.02; 2.11		1.92
0.63; 5.84		2.67
1.62; 4.41		2.35
1.22; 4.54		1.65
0.85; 3.23		1.61
0.79; 3.29		NANANANANANANANA
nab-paclitaxel plus placeboNANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANA
carboplatin plus nab-paclitaxelNANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANA
durvalumab aloneNANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANA
pembrolizumab aloneNA0.90
0.80; 1.02		NANANANANANANA0.68
0.42; 1.12		NANANA---1.11
0.91; 1.34		1.06
0.90; 1.25		NANA0.81
0.64; 1.03		1.06
0.82; 1.39		1.00
0.72; 1.40		1.31
0.47; 3.60		1.82
1.50; 2.21		1.60
1.01; 2.56		1.13
0.69; 1.83		1.10
0.64; 1.89		NANANANANANANANA
atezolizumab plus nab-paclitaxelNA0.81
0.70; 0.94		NANANANANANANA0.62
0.37; 1.01		NANANA0.90
0.75; 1.09		---0.96
0.80; 1.15		NANA0.73
0.57; 0.94		0.96
0.73; 1.27		0.91
0.64; 1.28		1.18
0.43; 3.26		1.64
1.33; 2.03		1.45
0.90; 2.33		1.02
0.62; 1.67		0.99
0.57; 1.72		NANANANANANANANA
pembrolizumab plus SoCNA0.85
0.76; 0.95		NANANANANANANA0.64
0.39; 1.05		NANANA0.94
0.80; 1.11		1.04
0.87; 1.26		---NANA0.76
0.60; 0.96		1.00
0.77; 1.30		0.95
0.68; 1.32		1.23
0.45; 3.39		1.72
1.42; 2.07		1.51
0.95; 2.41		1.06
0.66; 1.72		1.04
0.60; 1.78		NANANANANANANANA
atezolizumab based treatmentNANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANA
avelumab aloneNANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANA
atezolizumab plus paclitaxelNA1.12
0.91; 1.37		NANANANANANANA0.84
0.50; 1.42		NANANA1.24
0.98; 1.57		1.37
1.07; 1.77		1.31
1.04; 1.66		NANA---1.32
0.96; 1.80		1.24
0.85; 1.80		1.62
0.58; 4.52		2.25
1.75; 2.91		1.99
1.21; 3.26		1.40
0.84; 2.33		1.36
0.77; 2.40		NANANANANANANANA
talazoparibNA0.85
0.67; 1.07		NANANANANANANA0.64
0.38; 1.09		NANANA0.94
0.72; 1.23		1.04
0.79; 1.37		1.00
0.77; 1.29		NANA0.76
0.56; 1.04		---0.94
0.64; 1.39		1.23
0.44; 3.45		1.71
1.29; 2.26		1.51
0.91; 2.51		1.06
0.63; 1.79		1.03
0.58; 1.84		NANANANANANANANA
olaparibNA0.90
0.66; 1.23		NANANANANANANA0.68
0.47; 0.98		NANANA1.00
0.71; 1.39		1.10
0.78; 1.56		1.06
0.76; 1.47		NANA0.81
0.55; 1.17		1.06
0.72; 1.57		---1.30
0.46; 3.74		1.82
1.28; 2.57		1.60
0.93; 2.77		1.12
0.64; 1.98		1.10
0.59; 2.03		NANANANANANANANA
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamideNA0.69
0.25; 1.89		NANANANANANANA0.52
0.17; 1.59		NANANA0.77
0.28; 2.11		0.85
0.31; 2.34		0.81
0.29; 2.23		NANA0.62
0.22; 1.72		0.81
0.29; 2.29		0.77
0.27; 2.20		---1.39
0.50; 3.85		1.23
0.41; 3.69		0.86
0.28; 2.62		0.84
0.27; 2.62		NANANANANANANANA
sacituzumab govitecanNA0.50
0.43; 0.58		NANANANANANANA0.37
0.23; 0.62		NANANA0.55
0.45; 0.67		0.61
0.49; 0.75		0.58
0.48; 0.70		NANA0.44
0.34; 0.57		0.58
0.44; 0.77		0.55
0.39; 0.78		0.72
0.26; 1.99		---0.88
0.55; 1.42		0.62
0.38; 1.02		0.60
0.35; 1.05		NANANANANANANANA
capivasertib plus paclitaxelNA0.56
0.36; 0.88		NANANANANANANA0.42
0.22; 0.82		NANANA0.62
0.39; 0.99		0.69
0.43; 1.11		0.66
0.42; 1.05		NANA0.50
0.31; 0.83		0.66
0.40; 1.10		0.62
0.36; 1.08		0.82
0.27; 2.45		1.13
0.71; 1.82		---0.70
0.37; 1.35		0.69
0.34; 1.37		NANANANANANANANA
ipatasertib plus paclitaxelNA0.80
0.50; 1.28		NANANANANANANA0.60
0.31; 1.18		NANANA0.89
0.55; 1.44		0.98
0.60; 1.61		0.94
0.58; 1.52		NANA0.72
0.43; 1.20		0.94
0.56; 1.60		0.89
0.51; 1.56		1.16
0.38; 3.52		1.61
0.99; 2.64		1.42
0.74; 2.73		---0.98
0.48; 1.98		NANANANANANANANA
veliparib plus paclitaxel plus carboplatinNA0.82
0.48; 1.39		NANANANANANANA0.62
0.30; 1.26		NANANA0.91
0.53; 1.56		1.01
0.58; 1.74		0.96
0.56; 1.65		NANA0.73
0.42; 1.29		0.97
0.54; 1.72		0.91
0.49; 1.68		1.19
0.38; 3.70		1.65
0.96; 2.86		1.46
0.73; 2.92		1.02
0.51; 2.08		---NANANANANANANANA
nab-paclitaxel plus toripalimabNANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANA
camrelizumab aloneNANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANA
atezolizumab plus carboplatin plus nab-paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANA
camrelizumab plus SOCNANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANA
atezolizumab plus carboplatin plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANA
gemcitabine plus platinNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANA
docetaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NA
cyclophosphamideNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---

pathologies: 324,387,96,269,60,143,270,140,240,142,305,306,98 - treatments: 1570 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons